Novan Therapeutics' Positive Phase 2 Results Provide Foundation for SB204 as a Non-Antibiotic, First-in-Class Product to Treat Acne Vulgaris

SB204 Provides Basis for a Fast-Acting and Well-Tolerated Solution

DURHAM, NC (May 8, 2014) – Novan Therapeutics, a specialty pharmaceutical company focused on advancing nitric oxide therapies for a number of diseases, will present data from its Phase 2 clinical trial for its topical product candidate, SB204 in subjects with acne vulgaris today at the 2014 Annual Meeting of the Society for Investigative Dermatology (SID). The poster titled "Phase 2 study of efficacy and safety of SB204 in the treatment of acne vulgaris" will be presented by M. Joyce Rico, M.D., Chief Medical Officer for Novan.

"We exceeded our Phase 2 study goals and are very encouraged by SB204's rapid onset of action with statistically significant results. SB204 has the potential to significantly impact an acne market where dermatologists still rely heavily on topical and oral antibiotics despite the emergence of resistance," said Dr. Rico.

James J. Leyden, M.D., Penn Medicine, Perelman Center for Advanced Medicine said, "The recent attention from the CDC and global government agencies on the use of antibiotics and microbial resistance highlights the increasing need to curtail the overuse of antibiotics in dermatology." Dr. Leyden concluded, "SB204 provides a topical, non-antibiotic solution with demonstrated clinical activity against P. acnes."

The emergence of P. acnes resistance in acne is well documented and parallels the rise of superbugs that are able to evade the most effective antibiotics. As recent as last week, the World Health Organization cautions that the implications of the global threat of antibiotic resistance "will be devastating."

To view the poster use the following link:

To view the abstract use the following link:

About Novan, Inc.

Novan Therapeutics is a privately-held, clinical-stage specialty pharmaceutical company bringing the power of nitric oxide therapeutics to dermatology and wound care. Novan's core technologies solve the previous delivery issues with nitric oxide by storing the gaseous species on macromolecules that result in a diverse pipeline of "timed-release" nitric oxide-releasing new chemical entities. Novan is currently developing a range of drug products including topical gels, creams, ointments, and wound dressings which can be tailored to treat specific skin conditions.

To learn more about Novan Therapeutics, please visit


Rachel Shockley
Novan Therapeutics

Source: Novan Therapeutics

Back to News